Liver Fibrosis Market to Surge at a CAGR of 15.9% by 2032 | DelveInsight

The overall liver fibrosis market size is anticipated to increase owing to the rising prevalent cases. In addition, due to the lack of approved drugs, the expected launch of emerging therapy for liver fibrosis treatment will boost the liver fibrosis market in the forecasted period (2022–2032).

LAS VEGAS, Sept. 5, 2022 /PRNewswire/ -- DelveInsight's Liver Fibrosis Market Insights report includes a comprehensive understanding of current treatment practices, liver fibrosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan].

Key Takeaways from the Liver Fibrosis Market Report

• As per DelveInsight analysis, the liver fibrosis market size in the 7MM was approximately USD 2,225 million in 2021.
• As per the estimates, the total liver fibrosis diagnosed prevalent cases in the 7MM was approximately 19 million in 2021. 
• Leading liver fibrosis companies such as Inventiva Pharma, Galmed Research and Development, Ltd., Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, Galectin Therapeutics Inc., Zydus Therapeutics, Axcella Therapeutics, Akero Therapeutics, Inc, Lipocine Inc., Enyo Pharma, Sagimet Biosciences Inc., 89bio, Inc., HighTide Biopharma, Rivus Pharmaceuticals, Inc., Novo Nordisk A/S, and others are developing novel liver fibrosis drugs that can be available in the liver fibrosis market in the upcoming years.
• The liver fibrosis therapies in the pipeline include Lanifibranor, Aramchol, MGL-3196 (Resmetirom), Obeticholic Acid (Ocaliva), GR-MD-02 (Belapectin), Saroglitazar Magnesium, AXA1125, EFX, LPCN 1144, EYP001a (Vonafexor), TVB-2640 (Denifanstat), Pegozafermin (BIO89-100), HTD1801, HU6, Semaglutide, and others.
• The increase in liver fibrosis market size is a direct consequence of the expected approval of emerging therapy and the increasing patient population of liver fibrosis in the 7MM.

Discover which therapies are expected to grab major liver fibrosis market share @Liver Fibrosis Market Report

Liver Fibrosis Overview

Liver fibrosis is caused by an accumulation of extracellular matrix (ECM) proteins, primarily collagens Type I and Type III, which leads to the creation of fibrous scar tissue, which can eventually impede normal liver function. Chronic HCV infection, alcohol consumption, and non-alcoholic steatohepatitis (NASH) are the leading liver fibrosis causes in developed countries. Cirrhosis, liver failure, and portal hypertension are all liver fibrosis symptoms that typically necessitate a liver transplant. Abdominal ultrasound, computed tomography (CT) of the abdomen and pelvis, magnetic resonance imaging (MRI), ultrasound elastography, MR elastography (MRE), transient elastography, and liver biopsy are among the test used for liver fibrosis diagnosis.

Liver Fibrosis Epidemiology Segmentation

As per DelveInsight, there were approx 19 million liver fibrosis diagnosed prevalent cases in the 7MM in 2021.

Among the EU5 countries, Germany had the highest diagnosed prevalent cases of liver fibrosis in 2021.

The liver fibrosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Diagnosed Prevalent cases of Liver Fibrosis
• Severity-specific Diagnosed cases of Non-alcoholic Steatohepatitis (NASH)
• Total Diagnosed Prevalent cases of Liver fibrosis in NASH

Download the report to understand which factors are driving liver fibrosis epidemiology trends @Liver Fibrosis Epidemiological Insights

Liver Fibrosis Treatment Market 

Current liver fibrosis treatment options focus on removing associated damage causes, limiting hepatic stellate cell (HSC) activation, and boosting ECM breakdown and resistance to inflammatory responses. Other than treatment with traditional drugs, there are no specific therapeutic options for liver fibrosis treatment and early cirrhosis in clinics; traditional treatment methods have some problems, such as toxic and side effects on tissues and organs, as well as low drug selectivity, which cannot provide an effective concentration of therapeutic drugs into the liver.

Moreover, the significance of liver fibrosis extends beyond the liver's prognosis. As a result, treating concurrent disorders must be prioritized to enhance the prognosis of patients with NAFLD and fibrosis. To guarantee long-term adherence, the therapy considers the presence of comorbidities and the patient's preferences. Due to a lack of standard liver fibrosis treatment options, liver transplantation is the sole choice for severe and advanced instances of fibrosis. The FDA has not authorized therapy for fibrosis or NASH; however, a few studies have shown encouraging outcomes.

To know more about liver fibrosis treatment, visit @New Treatment for Liver Fibrosis 

Liver Fibrosis Pipeline Therapies and Key Companies

• Lanifibranor: Inventiva Pharma
• Aramchol: Galmed Research and Development, Ltd.
• MGL-3196 (Resmetirom): Madrigal Pharmaceuticals, Inc.
• Obeticholic Acid (Ocaliva): Intercept Pharmaceuticals
• GR-MD-02 (Belapectin): Galectin Therapeutics Inc.
• Saroglitazar Magnesium: Zydus Therapeutics
• AXA1125: Axcella Therapeutics
• EFX: Akero Therapeutics, Inc
• LPCN 1144: Lipocine Inc.
• EYP001a (Vonafexor): Enyo Pharma
• TVB-2640 (Denifanstat): Sagimet Biosciences Inc.
• Pegozafermin (BIO89-100): 89bio, Inc.
• HTD1801: HighTide Biopharma
• HU6: Rivus Pharmaceuticals, Inc.
• Semaglutide: Novo Nordisk A/S

Learn more about the liver fibrosis therapies in clinical trials @Drugs for Liver Fibrosis Treatment 

Liver Fibrosis Market Dynamics

The dynamics of the liver fibrosis market are expected to change due to the increased awareness of the disease. In addition, a better understanding of the pathophysiology is also a vital factor driving the growth of the liver fibrosis market. Moreover, a large variety of potential anti-fibrotic therapies targeting liver fibrosis are now in clinical studies, and any success will directly address fibrosis, thus boosting the growth of the liver fibrosis market. 

Additionally, there is no approved therapy in the therapeutic landscape; the liver fibrosis market is projected to see considerable penetration of the first licensed drug in the treatment of fibrosis. Furthermore, leading companies worldwide have worked hard to develop novel treatment methods with varying degrees of success. Moreover, the robust emerging pipeline is also bolstering the liver fibrosis market growth. 

However, certain factors are limiting the growth of the liver fibrosis market. The undiagnosed, unreported cases and the persisting limited awareness about the disease remain the primary aspects that strive for the liver fibrosis market growth. Moreover, liver fibrosis was thought to be irreversible, but advances in study on the molecular pathophysiology of liver fibrosis have demonstrated that hepatic cellular recovery is feasible. 

Other than removing the fibrogenic stimulation, there are currently no approved treatment options for treating this potentially fatal condition. Biopsy-confirmed fibrosis is linked with mortality risk and liver-related morbidity in patients with NAFLD, with and without adjustment for confounding variables, and in individuals with reported NASH, according to systematic reviews and meta-analyses on hepatic fibrosis. 

Furthermore, the high disease burden and complex mechanisms are also prominent aspects hindering the growth of the liver fibrosis market. 

Scope of the Liver Fibrosis Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Liver Fibrosis Companies: Inventiva Pharma, Galmed Research and Development, Ltd., Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, Galectin Therapeutics Inc., Zydus Therapeutics, Axcella Therapeutics, Akero Therapeutics, Inc, Lipocine Inc., Enyo Pharma, Sagimet Biosciences Inc., 89bio, Inc., HighTide Biopharma, Rivus Pharmaceuticals, Inc., Novo Nordisk A/S, and others
• Key Liver Fibrosis Therapies: Lanifibranor, Aramchol, MGL-3196 (Resmetirom), Obeticholic Acid (Ocaliva), GR-MD-02 (Belapectin), Saroglitazar Magnesium, AXA1125, EFX, LPCN 1144, EYP001a (Vonafexor), TVB-2640 (Denifanstat), Pegozafermin (BIO89-100), HTD1801, HU6, Semaglutide, and others
• Therapeutic Assessment: Liver Fibrosis current marketed and emerging therapies
• Liver Fibrosis Market Dynamics:  Liver Fibrosis market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Liver Fibrosis Market Access and Reimbursement

Discover more about new drugs for liver fibrosis in development @Liver Fibrosis Clinical Trials

Table of Contents

Get in touch with our Business executive @Healthcare Due Diligence Services 

Related Reports

Liver Fibrosis Epidemiology

Liver Fibrosis Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted liver fibrosis epidemiology in the 7MM.

Liver Fibrosis Pipeline

Liver Fibrosis Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key liver fibrosis companies, including Intercept Pharmaceuticals, Galectin Therapeutics Inc., Zydus Therapeutics, among others.

Non-alcoholic Fatty Liver Disease Market

Non-alcoholic Fatty Liver Disease Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key non-alcoholic fatty liver disease companies including AstraZeneca, Novartis, Pfizer, Roche, among others.

Non-alcoholic Fatty Liver Disease Pipeline

Non-alcoholic Fatty Liver Disease Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-alcoholic fatty liver disease companies including AstraZeneca, Novartis, Pfizer, Roche, among others.

Non-alcoholic Steatohepatitis Market

Non-alcoholic Steatohepatitis Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key non-alcoholic steatohepatitis companies including Zydus Cadila, Novartis, AstraZeneca, among others.

Non-alcoholic Steatohepatitis Pipeline

Non-alcoholic Steatohepatitis Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-alcoholic steatohepatitis companies, including AstraZeneca, Novartis, Zydus Cadila, among others.

Other Trending Reports

Persistent Depressive Disorder Market | Gene Therapy for Ocular Rare Disease Market | Congestive Heart Failure Market | CRISPR Therapies Pipeline | Desmoplastic Small Round Cell Tumors Market | India Healthcare Outlook Report | Psychosis Market | Dental Lasers Market | Primary Immune Deficiency Market I Dyslipidemia Market | Lateral Epicondylitis Disease Market | Castration-Resistant Prostate Cancer Market | Metrorrhagia Market | Global Messenger RNA-based Vaccines and Therapeutics Market | Negative Pressure Wound Therapy Systems Market | US Healthcare Outlook Report | Mucinous Cystic Neoplasms Market | Hot Flashes Market | Varicose Veins - Market | Hemostats Market | Injectable Drug Delivery Devices Market | Breast Pumps Market | Physiotherapy Equipment Market | Trastuzumab Biosimilars Insight | Deep Brain Stimulation Devices Market | Retinoblastoma Market | Venous Stenosis Market | Tumor Ablation Market | Substance Abuse Market | Insulin Glargine Biosimilar Insight | Interspinous Spacers Market | Anti-hypertension Market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg